FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
0.320
0.00 (0.00%)
At close: Oct 24, 2024, 4:00 PM
0.328
+0.008 (2.47%)
After-hours: Oct 24, 2024, 4:06 PM EDT
FibroGen Revenue
FibroGen had revenue of $50.64M in the quarter ending June 30, 2024, with 14.26% growth. This brings the company's revenue in the last twelve months to $173.82M, up 33.11% year-over-year. In the year 2023, FibroGen had annual revenue of $147.75M with 4.99% growth.
Revenue (ttm)
$173.82M
Revenue Growth
+33.11%
P/S Ratio
0.18
Revenue / Employee
$357,646
Employees
486
Market Cap
32.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 147.75M | 7.02M | 4.99% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 10.16M |
| Moolec Science | 5.63M |
| Daré Bioscience | 2.84M |
| Singular Genomics Systems | 2.72M |
| Dyadic International | 1.80M |
| Longeveron | 1.23M |
FGEN News
- 2 months ago - FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program - Benzinga
- 3 months ago - FibroGen to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward - Seeking Alpha
- 5 months ago - FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials - GlobeNewsWire
- 5 months ago - FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors - GlobeNewsWire
- 5 months ago - FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology - GlobeNewsWire
- 6 months ago - FibroGen to Participate in Upcoming Investor Conferences - GlobeNewsWire